Visionary Horizons
AXSM icon

Visionary Horizons’s Axsome Therapeutics AXSM Stock Holding History

Visionary Horizons’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-968
Closed -$237K – 148
2026
Q2 		$237K Buy
+968
New +$210K 0.1% 133

Other funds holding AXSM

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return

Visionary Horizons's AXSM Position: Q3 2026 in Review

Visionary Horizons sold out of Axsome Therapeutics (AXSM) in Q3 2026, closing a stake of 968 shares — an estimated $237K sold.

Visionary Horizons first reported a position in AXSM in Q2 2026 and held it in 1 quarter. The position peaked at $237K in Q2 2026. 206 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Visionary Horizons reported no remaining Axsome Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Visionary Horizons sold 968 Axsome Therapeutics shares in Q3 2026, an estimated $237K.
  • Visionary Horizons first reported a position in Axsome Therapeutics in Q2 2026 and held it in 1 quarter.
  • Visionary Horizons's Axsome Therapeutics position peaked at $237K in Q2 2026.
  • 206 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Visionary Horizons's 13F filing for Q3 2026, filed 22 Oct 2026.